Nifty 50
Tools & Calculators
Stocks
F&O
Mutual Funds
Sector: Pharmaceuticals & Biotechnology
|Large Cap
ACUTAAS
₹3,171
₹3155.00
₹3244.70
₹1302.00
₹3740.00
Markets Today
Historical Performance
As of 25-08-2026 00:02, Acutaas Chemicals Ltd. share price today is ₹0, with a change of ₹-3169.00 (-100.00%) from the previous close of ₹3169. The stock opened at ₹3189.1 and traded between ₹3155 and ₹3244.7, with a total traded volume of 360245 shares. The company has a market capitalization of ₹25945 Cr in the Pharmaceuticals & Biotechnology sector. while its 52-week high and low are ₹3740 and ₹1302, respectively.
Acutaas Chemicals Ltd. valuation metrics include a P/E ratio of 67.2, EPS of ₹43.51, and book value of ₹15.00. Profitability indicators show ROE of 21.54%. Acutaas Chemicals Ltd. has reported revenue of ₹1461.8 Cr and net profit of ₹386.22 Cr.
Acutaas Chemicals Ltd. technical indicators include Day RSI at 44.49, Day MFI at 49.33, Day ADX at 23.85. Additional indicators include Commodity Channel Index (CCI) at -47.6 and Williams %R at -65.98. Momentum indicators show Day MACD at -38.45, Day MACD Signal Line at -36.79, DayATR at 135.42. Rate of Change indicators for Acutaas Chemicals Ltd. include ROC125 at 52.66 and ROC21 at -8.39.
Exponential moving averages include EMA5 at ₹3215.5, EMA10 at ₹3229, EMA12 at ₹3235.2, EMA20 at ₹3261.6, EMA26 at ₹3273.7, EMA50 at ₹3239.6, EMA100 at ₹3012.7, EMA200 at ₹2587.8. Simple moving averages include SMA5 at ₹3239.6, SMA10 at ₹3222.6, SMA20 at ₹3235.9, SMA30 at ₹3337.8, SMA50 at ₹3342.4, SMA100 at ₹3020.1, SMA150 at ₹2694.2, SMA200 at ₹2450.8.
Support levels for Acutaas Chemicals are placed at First Support ₹3133.00, Second Support ₹3097.00, Third Support ₹3034.00. Resistance levels are seen at First Resistance ₹3232.00, Second Resistance ₹3295.00, Third Resistance ₹3331.00. Acutaas Chemicals Ltd. shareholding pattern shows promoter holding at 32.66%, FII holding at 21.61%, DII holding at 0%, public holding at 26.16%.
Indicator | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Total Revenue | 322.41 | 421.77 | 390.86 | 305.19 | 205.97 |
| Operating Expense | 212.73 | 240.56 | 236.66 | 208.59 | 154.98 |
| Operating Profit | 109.68 | 181.22 | 154.19 | 96.61 | 50.99 |
| Depreciation | 9.02 | 8.83 | 9.02 | 7.72 | 7.46 |
| Interest | 1.12 | 1.07 | 0.81 | 0.57 | 0.62 |
| Tax | 28.12 | 48.79 | 39.14 | 24.39 | 14.28 |
| Net Profit | 75.90 | 137.07 | 111.57 | 72.89 | 44.65 |
₹3171.00
↗ Bullish Moving Average
5
↘ Bearish Moving Average
11
| Held By | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoter | 36 | 32.7 | 32.7 | 32.7 | 32.7 | 32.7 |
| FII | 16.5 | 16.9 | 16.8 | 16.7 | 19.5 | 21.6 |
| DII | 18.3 | 22.4 | 22.6 | 21.7 | 19.6 | 19.6 |
| Public | 29.2 | 28 | 27.9 | 29 | 28.2 | 26.2 |
| Period | Combined Delivery Volume | NSE+BSE Traded Volume Avg | Daily Avg Delivery Volume % |
|---|---|---|---|
| Day | 2.06 L | 2.91 L | 70.59% |
| Week | 1.62 L | 3.04 L | 53.32% |
| 1 Month | 1.98 L | 4.14 L | 47.67% |
| 6 Month | 2.27 L | 5 L | 45.47% |
Benjamin Graham Value Screen
Consistent high performing stocks over Five Years
Relative Outperformance versus Industry over 1 Year
Companies with high TTM EPS Growth
Growth Stars: Strongest Annual EPS Performers
Expensive Performers (DVM)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Annual Net Profits improving for last 2 years
Companies with Zero Promoter Pledge
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Highest Recovery from 52 Week Low
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 18 Sep, 2025 | 1.5 | FINAL | 18 Sep, 2025 | Equity Share |
| 13 Sep, 2024 | 3 | FINAL | 13 Sep, 2024 | Equity Share |
| 18 Sep, 2023 | 3 | FINAL | 18 Sep, 2023 | Equity Share |
| 29 Jul, 2022 | 3 | FINAL | 01 Aug, 2022 | Equity Share |
Financials | ||||||
|---|---|---|---|---|---|---|
| Price (₹) | ₹1,766 | ₹883.60 | ₹1,436.80 | ₹1,862 | ₹2,374.50 | ₹212.43 |
| % Change | 2.39% | 1.39% | -1.41% | -0.05% | -0.40% | -0.58% |
| Revenue TTM (₹ Cr) | ₹1,935.80 | ₹2,002.34 | ₹2,250.36 | ₹9,683.45 | ₹14,737.88 | ₹9,205.28 |
| Net Profit TTM (₹ Cr) | ₹288.22 | ₹575.94 | ₹361.74 | ₹1,011.39 | ₹2,042.67 | ₹-313.62 |
| PE TTM | 99.10 | 85.20 | 85.50 | 34.90 | 48.20 | -90.70 |
| 1 Year Return | 255.61 | 5.9 | 57.4 | 24.77 | -8.55 | 10.85 |
| ROCE | 24.32 | 27.56 | 18.38 | 25.65 | 14.32 | 2.29 |
Gland Pharma Ltd.
₹ 2811.90
-0.26%
Laurus Labs Ltd.
₹ 1801.00
-0.06%
Alkem Laboratories Ltd.
₹ 5350.00
-0.93%
Biocon Ltd.
₹ 409.40
-1.48%
Divi's Laboratories Ltd.
₹ 8496.00
-1.17%
Granules India Ltd.
₹ 857.00
-0.13%
Ajanta Pharma Ltd.
₹ 3581.00
-1.62%
Zydus Lifesciences Ltd.
₹ 1103.80
-1.45%
Glenmark Pharmaceuticals Ltd.
₹ 2390.70
+3.14%
Wockhardt Ltd.
₹ 1902.00
+0.83%
Aurobindo Pharma Ltd.
₹ 1608.00
-0.82%
Sun Pharmaceutical Industries Ltd.
₹ 1910.00
+0.40%
Neuland Laboratories Ltd.
₹ 22901.00
-1.72%
Ipca Laboratories Ltd.
₹ 1921.00
+0.51%
GlaxoSmithKline Pharmaceuticals Ltd.
₹ 2930.00
+0.96%
Pfizer Ltd.
₹ 4886.00
-1.85%
Abbott India Ltd.
₹ 26450.00
+0.84%
Torrent Pharmaceuticals Ltd.
₹ 4886.50
-0.20%
Lupin Ltd.
₹ 2188.00
-0.63%
Dr. Reddy's Laboratories Ltd.
₹ 1190.00
+1.30%
Cipla Ltd.
₹ 1437.90
+0.40%
By signing up I certify terms, conditions & privacy policy